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Abstract: UV radiation (UV) is classified as a ―complete carcinogen‖ because it is both a 
mutagen and a non-specific damaging agent and has properties of both a tumor initiator 
and a tumor promoter. In environmental abundance, UV is the most important modifiable 
risk factor for skin cancer and many other environmentally-influenced skin disorders. 
However, UV also benefits human health by mediating natural synthesis of vitamin D and 
endorphins in the skin, therefore UV has complex and mixed effects on human health. 
Nonetheless, excessive exposure to UV carries profound health risks, including atrophy, 
pigmentary changes, wrinkling and malignancy. UV is epidemiologically and molecularly 
linked to the three most common types of skin cancer, basal cell carcinoma, squamous cell 
carcinoma and malignant melanoma, which together affect more than a million Americans 
annually. Genetic factors also influence risk of UV-mediated skin disease. Polymorphisms 
of the melanocortin 1 receptor (MC1R) gene, in particular, correlate with fairness of skin, 
UV sensitivity, and enhanced cancer risk. We are interested in developing UV-protective 
approaches based on a detailed understanding of molecular events that occur after UV 
exposure, focusing particularly on epidermal melanization and the role of the MC1R in 
genome maintenance.  
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1. The Skin  
Comprising roughly 16% of body mass, the skin is the largest organ of the body. Skin is  
organized into two primary layers, epidermis and dermis, which together are made up of epithelial, 
mesenchymal, glandular and neurovascular components. The epidermis, of ectodermal origin, is the 
outermost layer and serves as the body’s point of contact with the environment. As such, epidermal 
biological and physical characteristics play an enormous role in resistance to environmental stressors 
such as infectious pathogens, chemical agents and UV [1–6]. Keratinocytes are the most abundant cells 
in the epidermis and are characterized by their expression of cytokeratins and formation of desmosomes 
and tight junctions with each other to form an effective physicochemical barrier. The dermis, derived 
from mesoderm, underlies the epidermis and harbors cutaneous structures including hair follicles, 
nerves, sebaceous glands and sweat glands. The dermis also contains abundant immune cells and 
fibroblasts, which actively participate in many physiologic responses in the skin. The epidermis, 
demarcated from the dermis by a basement membrane, is organized into functional layers defined 
largely by keratinocyte characteristics such as size, shape, nucleation and keratin expression [7] 
(Figure 1). Nascent epidermal keratinocytes formed as a result of cell division by keratinocyte stem 
cells in the stratum basale undergo a programmed differentiation as they migrate outward toward the 
surface of the skin to eventually form corneocytes, which are tightly-linked dead but intact cells that 
form the principle barrier of the outermost epidermal layer [8,9].  
Besides the creation of a highly effective physical barrier, keratinocytes also accumulate melanin 
pigments as they mature, and epidermal melanin functions to potently block UV penetration into the 
skin. Although melanin may be found in abundance in epidermal keratinocytes, it is not manufactured 
in these cells. Rather, melanin synthesis is restricted to melanocytes, which are derived from neural 
crest and are the second most abundant cell in the epidermis [10,11]. In fact, melanocytes can be found 
both in the dermis and epidermis. Epidermal melanocytes are generally positioned in the basal layer 
above the basement membrane. Melanocytes are also found in hair follicles to impart pigment to 
nascent hair [12]. Dermal melanocytes can be found in nevi (moles). Because melanocytes are the only 
source of pigment in the skin, inherited pigmentary defects such as albinism tend to be caused by 
melanocytic genetic defects [10,13]. Through dendritic extensions, melanocytes may be in intimate 
contact with as many as fifty neighboring keratinocytes in what is known as an ―epidermal melanin 
unit‖ [11,14]. There are many contact-dependent and paracrine interactions that occur between 
keratinocytes and melanocytes in the epidermal melanin unit. Pigment made by melanocytes is 
transferred to adjacent keratinocytes in cellular organelles termed melanosomes by way of melanocytic 
dendrites [15–17]. In fact, most of the melanin in the skin is found in keratinocytes where it 
accumulates to function as a ―natural sunscreen‖ to protect the skin against incoming UV photons. 
Besides blocking UV penetration into the skin, melanin may have many other important physiologic 
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effects including regulatory influences over epidermal homeostasis, free radical scavenging to protect 
against oxidative injury, and possibly even antimicrobial activity [10,18–24]. 
Figure 1. Epidermal structure and keratinocyte differentiation. The epidermis is a  
self-renewing tissue composed mainly of keratinocytes in various stages of terminal 
differentiation. Keratinocytes are produced in the stratum basale (basal layer), and move 
outward through the epidermis, undergoing a programmed series of differentiation 
involving enucleation and accumulation of cytokeratins and tight junctions with each other. 
Keratinocytes also receive melanin from melanocytes in the form of pre-packaged 
organelles termed melanosomes. The basic layers from the basement membrane outward 
are the stratum basale, stratum spinosum, stratum granulosum, and the stratum corneum, 
each identified by the morphology and differentiation state of the keratinocyte as indicated 
by expression of cytokeratins and other proteins. 
 
2. Melanin  
The amount and type of epidermal melanin is the main factor that determines skin complexion and 
UV sensitivity. Melanin is a large bio-aggregate composed of subunits of different pigment species 
formed by oxidation and cyclization of the amino acid tyrosine [10,25,26] (Figure 2). Intriguingly, the 
intermediates of melanogenesis may have important regulatory roles in the skin [27–29]. Melanin 
exists in two main chemical forms: (1) eumelanin, a dark pigment expressed abundantly in the skin of 
heavily pigmented individuals, and (2) pheomelanin, a light-colored sulfated pigment resulting from 
incorporation of cysteines into melanin precursors [30]. Eumelanin is much more efficient at blocking 
UV photons than pheomelanin, thus the more eumelanin in the skin, the less UV-permeable is the 
epidermis [31]. Fair-skinned people who are almost always UV-sensitive and have high risk of skin 
cancer have little epidermal eumelanin and therefore ―realize‖ much more UV than darker-skinned 
individuals. Therefore, the fairer the skin, the more damaging UV exposure will be. In fact, pheomelanin 
levels are similar between dark-skinned and light-skinned individuals, and it is the amount of 
epidermal eumelanin that determines skin complexion, UV sensitivity and cancer risk. Data suggest 
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that pheomelanin may promote oxidative DNA injury and melanomagenesis by generating free 
radicals in melanocytes even in the absence of UV [32–37].  
Figure 2. Melanin Biosynthesis. Melanin, a large bioaggregate composed of pigmented 
chemical species, is found in two major forms: the brown/black highly UV-protective 
―eumelanin‖ pigment and the red/blonde UV-permeable ―pheomelanin‖. Both eumelanin 
and pheomelanin are derived from the amino acid tyrosine. Tyrosinase is the enzyme that 
catalyzes the rate-limiting synthetic reaction for both melanin species and when defective 
causes albinism. Incorporation of cysteine into pheomelanin results in the retention of sulfur 
into the pigment, which yields a light color to the final melanin product and may contribute 
to oxidative injury in the skin. The melanocyte stimulating hormone (MSH)–melanocortin 
1 receptor (MC1R) signaling axis is a major determinant of the type and amount of melanin 
produced by melanocytes in the skin. 
 
3. Skin Pigmentation  
Skin complexion is among the most important determinants of UV sensitivity and skin cancer risk. 
The ―Fitzpatrick Scale‖ is a semi-quantitative scale made up of six phototypes that describe skin color 
by basal complexion, melanin level, inflammatory response to UV and cancer risk [13] (Table 1). 
Minimal erythematous dose (MED) is a quantitative method to report the amount of UV (particularly 
UVB) needed to induce sunburn in the skin 24–48 h after exposure by determining erythema (redness) 
and edema (swelling) as endpoints. The fairer the skin, the easier it is for UV to cause inflammation 
(sunburn). MED, therefore is highest in dark-skinned persons since more UV radiation is needed to 
―burn‖ eumelanin-rich skin [38–40]. In contrast, fair-skinned people whose skin expresses predominantly 
pheomelanin have low MEDs. Low Fitzpatrick phototype correlates with both MED and with 
melanoma and other skin cancer risk [41].  
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Table 1. Skin pigmentation, the Fitzpatrick scale and UV risk.  
Fitzpatrick 
phototype 
Phenotype 
Epidermal 
eumelanin 
Cutaneous response to UV 
MED 
(mJ/cm
2
) *
 
Cancer 
risk 
I 
Unexposed skin is bright white 
Blue/green eyes typical 
Freckling frequent 
Northern European/British 
+/− 
Always burns 
Peels 
Never tans 
15–30 ++++ 
II 
Unexposed skin is white 
Blue, hazel or brown eyes 
Red, blonde or brown hair 
European/Scandinavian 
+ 
Burns easily 
Peels 
Tans minimally 
25–40 +++/++++ 
III 
Unexposed skin is fair 
Brown eyes 
Dark hair 
Southern or Central European 
++ 
Burns moderately 
Average tanning ability 
30–50 +++ 
IV 
Unexposed skin is light brown 
Dark eyes 
Dark hair 
Mediterranean, Asian or Latino 
+++ 
Burns minimally 
Tans easily 
40–60 ++ 
V 
Unexposed skin is brown 
Dark eyes 
Dark hair 
East Indian, Native American, 
Latino or African 
++++ 
Rarely burns 
Tans easily and substantially 
60–90 + 
VI 
Unexposed skin is black 
Dark eyes 
Dark hair 
African or Aboriginal ancestry 
+++++ 
Almost never burns 
Tans readily and profusely 
90–150 +/− 
Minimal erythematous dose (MED) is defined as the least amount of UVB radiation that causes reddening and 
inflammation of the skin 24–48 h after exposure (i.e., the lowest UV dose that causes sunburn). The more UV sensitive an 
individual is, the lower the MED of his/her skin. 
4. Ultraviolet Radiation (UV) 
Abundant in the environment, UV contributes to a variety of skin maladies including inflammation, 
degenerative aging and cancer [1]. Historically, humans have been exposed to UV radiation mainly 
through occupational exposure to sunlight. Recreational UV exposure, however, has increased 
dramatically in recent years because of outdoor leisure activities and to purposely tan for cosmetic 
purposes [42,43]. Being a component of the electromagnetic spectrum, UV photons fall between the 
wavelengths of visible light and gamma radiation. UV energy can be subdivided into UV-A, -B and -C 
components based on electro physical properties, with UV-C photons having the shortest wavelengths 
(100–280 nm) and highest energy, UV-A having the longest (315–400 nm) but least energetic photons 
and UV-B falling in between (Figure 3). Each component of UV can exert a variety of effects on cells, 
tissues and molecules. 
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Figure 3. Electromagnetic spectrum of visible and UV radiation and biologic effects on the 
skin. Solar UV radiation can be subdivided into UVA, UVB and UVC components, 
however because of atmospheric ozone that absorbs UVC, ambient sunlight is predominantly 
UVA (90%–95%) and UVB (5%–10%). UV penetrates the skin in a wavelength- 
dependent manner. Longer wavelength UVA penetrates deeply into the dermis reaching 
well into the dermis. In contrast, UVB is almost completely absorbed by the epidermis, with 
comparatively little reaching the dermis. UVA is efficient at generating reactive oxygen 
species that can damage DNA via indirect photosensitizing reactions. UVB is directly 
absorbed by DNA which causes molecular rearrangements forming the specific 
photoproducts such as cyclobutane dimers and 6–4 photoproducts. Mutations and cancer 
can result from many of these modifications to DNA. 
 
Ambient UV exposure varies geographically according to intensity of sunlight in a particular 
location on Earth. Since UV radiation can be reflected, scattered and dampened by atmospheric 
particles, ambient UV dose varies according to the amount of atmosphere it must pass through, making 
UV doses higher nearest the Equator (where sunlight strikes the Earth most directly), at higher 
altitudes and in conditions of minimal cloud or particulate cover. Personal UV dosing depends not only 
on strength of solar radiation, but also on time spent outdoors occupationally or recreationally and the 
usage of UV-protective clothing, shade and sun blocks. Since equatorial locations tend to be warm and 
conducive to recreational or occupational outdoor activities, people living such locales typically wear 
less clothing and have more contact with ambient sunlight and usually receive much higher ambient 
UV doses than persons inhabiting temperate climates. Not surprisingly, skin cancer risk generally 
mirrors this geographic pattern, particularly among fair-skinned sun-sensitive persons [44–46].  
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5. Indoor Tanning  
The number and use of indoor tanning salons has skyrocketed over the last several years. In 
America alone, only 1% of the population had ever used a tanning bed in the late 1980s. Now it is 
estimated that over 25% of Americans have engaged in purposeful exposure to artificial UV  
radiation [47]. Indoor tanning is an important industry with nearly 30 million clients, 100,000 employees 
and billions of dollars of annual business. Indoor tanning machines are poorly regulated and vary widely 
with respect to UV composition and strength. UV output from tanning beds can be up to ten times 
more powerful than sunlight [48,49], making the tanning bed an authentic carcinogenic instrument. 
Tanning can be addictive, leading to frequent and significant UV exposure over time [50–52], and 
since tanning often appeals to adolescents and young adults, tanning patrons’ UV history can be 
significant for many years [53].  
Indoor tanning clearly increases incidence of skin cancers [54,55]. With respect to melanoma, the 
deadliest of skin malignancies, lifetime risk increases by 75% if people engage in artificial tanning 
before the age of 35 years [56–58]. Cancer risk increases with years of use, number of sessions, and 
total number of UV h exposed [54,56,59,60]. Since the molecular pathways in the skin that activate 
UV-induced tanning result from cellular and DNA damage which underlie skin damage and 
carcinogenesis (Figure 4), it appears as though there is no ―safe‖ use of tanning salons [57]. The 
tanning industry has engaged a powerful political lobby to further its commercial interests by downplaying 
the adverse health risks of UV. Instead, the industry publicizes the health benefits of UV to its clients, 
emphasizing vitamin D production which is naturally made in the skin by the chemical conversion of 
7-dehydrocholesterol into vitamin D3 (cholecalciferol) after UVB exposure [61–69]. In fact, UV doses 
that induce tanning far exceed what is required for adequate vitamin D production and the widespread 
availability of vitamin D in supplements and fortified foods minimizes the need for UV exposure to 
avoid symptoms of rickets and vitamin D deficiency [70–74]. Multiple studies report overwhelming 
evidence that the risks of indoor tanning far outweigh potential health benefits, most significantly for 
malignancy. Decreasing UV radiation exposure, both naturally from sunlight and artificially from tanning 
bed use, may be the single best way to reduce incidence of melanoma and other skin cancers [75].  
6. Cutaneous Responses to UV 
UV has many effects on skin physiology, with some consequences occurring acutely and others in a 
delayed manner. One of the most obvious acute effects of UV on the skin is the induction of inflammation. 
UVB induces a cascade of cytokines, vasoactive and neuroactive mediators in the skin that together 
result in an inflammatory response and causes ―sunburn‖ [3,4,6,76–79]. If the dose of UV exceeds  
a threshold damage response, keratinocytes activate apoptotic pathways and die. Such apoptotic 
keratinocytes can be identified by their pyknotic nuclei and are known as ―sunburn cells‖ [80]. UV 
also leads to an increase in epidermal thickness, termed hyperkeratosis. By causing cell injury, UV 
induces damage response pathways in keratinocytes. Damage signals such as p53 activation 
profoundly alter keratinocyte physiology, mediating cell cycle arrest, activating DNA repair and 
inducing apoptosis if the damage is sufficiently great. Several h after UV exposure, however, and 
damage response signals abate, epidermal keratinocytes proliferate robustly [81], mediated by a variety 
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of epidermal growth factors. Increased keratinocyte cell division after UV exposure leads to 
accumulation of epidermal keratinocytes which increases epidermal thickness. Epidermal hyperplasia 
protects the skin better against UV penetration [82].  
Figure 4. Mechanisms of the physiologic tanning response. Hormonal interactions between 
epidermal keratinocytes and melanocytes mediate much of the cutaneous melanization 
response. DNA and cellular damage in keratinocytes up-regulates transcription of the  
pro-opiomelanocortin (POMC) gene which encodes production and secretion of 
melanocyte stimulating hormone (α-MSH). α-MSH binding to melanocortin 1 receptor 
(MC1R) on melanocytes in the basal epidermis generates the second messenger cAMP via 
interactions between MC1R and adenylyl cyclase, and leads to activation of protein kinase 
A and the cAMP responsive binding element (CREB) and microphthalmia (Mitf) transcription 
factors. CREB and Mitf directly enhance melanin production by raising levels of tyrosinase 
and other melanin biosynthetic enzymes. Thus, MSH-MC1R signaling leads to enhanced 
pigment synthesis by melanocytes and accumulation of melanin by epidermal keratinocytes. 
By this mechanism, the skin is better protected against UV insults. Of note, UV-induced 
pigmentation may also occur through other signaling pathways as well as direct effects of 
UV on melanocytes, and there is some disagreement in the field over the role of epidermal 
MSH in the adaptive pigmentary response.  
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Coupled with epidermal hyperkeratosis is adaptive melanization of the skin, also known as  
tanning [4,10,83–86]. UV up-regulates production and epidermal accumulation of melanin pigment in 
the skin [87–91]. This important physiologic response protects the skin against subsequent UV damage, 
and defects in this pathway are linked with cancer susceptibility. UV-mediated skin darkening is actually 
biphasic, with initial skin darkening occurring from redistribution and/or molecular changes to existing 
epidermal melanin pigments. Delayed increases in skin darkening, mediated by actual up-regulation in 
melanin synthesis and transfer to keratinocytes, begin several h to days after UV exposure [92,93]. 
Adaptive melanization is likely a complex physiologic response [4,10,83,85] involving multiple skin 
cell types interacting in a variety of ways (Figure 4) [86,94–102]. UV has many other effects on the 
skin, including induction of an immune-tolerant or immunosuppressive state [103–110] and production 
of vitamin D by direct conversion of 7-dehydrocholesterol into vitamin D3 (cholecalciferol) [61–69]. 
Ambient sunlight, for the most part, is a mixture of UVA and UVB, yet each UV component may exert 
different and distinct effects on the skin [111,112]. UVB, for example, is a potent stimulator of 
inflammation and the formation of DNA photolesions (such as mutagenic thymine dimers) [112,113], 
whereas UVA is much less active in these measures but instead is a potent driver of oxidative free 
radical damage to DNA and other macromolecules [114–116]. Thus, each may contribute to 
carcinogenesis through different mechanisms [117–119]. The influence of UVA and UVB on skin 
physiology is an active area of investigation.  
7. Oxidative Injury 
Besides promoting formation of photodimers in the genome, UV causes mutations by generating 
reactive oxygen species (ROS) such as superoxide anion, hydrogen peroxide and the hydroxyl  
radical [21] (Figure 5). Nucleotides are highly susceptible to free radical injury. Oxidation of 
nucleotide bases promotes mispairing outside of normal Watson-Crick parameters, causing 
mutagenesis [120]. The transversion guanine→thymine, for example, is a well-characterized mutation 
caused by ROS by oxidizing guanine at the 8th position to produce 8-hydroxy-2'-deoxyguanine  
(8-OHdG) [121,122]. 8-OHdG tends to pair with an adenine instead of cytosine and therefore this 
oxidative change mutates a G/C pair into an A/T pair. Such mutations can be found in tumors isolated 
from the skin, suggesting that oxidative injury can be carcinogenic [123]. Cellular maintenance 
pathways exist to inactivate oxidative species as well as to repair the DNA damage they cause. The 
base excision repair pathway (BER) is the main molecular means by which cells reverse free radical 
damage in DNA to avoid oxidative mutagenesis. This pathway is initiated by damage-specific 
glycosylases that scan DNA for specific alterations including deaminated, alkylated or oxidized bases. 
After altered or inappropriate bases are recognized by a lesion-specific glycosylase, the enzyme 
cleaves the nucleotide base from the sugar and phosphodiesterase backbone by lysis of the  
N-glycosylic bond between the base and the deoxyribose. This step forms an abasic or 
apurinic/apyrimidinic (AP) site in the DNA, which is then processed and repaired using the 
complementary strand as a template to ensure fidelity.  
Cells also have a complex and robust network of anti-oxidant molecules that detoxify reactive 
species to prevent free radical changes to DNA and other macromolecules. Glutathione (GSH) is an 
oligopeptide made up of three amino acids- cysteine, glycine and glutamine and is among the most 
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important cellular antioxidant molecules. By donating electrons to otherwise reactive molecules, GSH 
functions as a reducing agent to neutralize reactivity of free radicals. In the process, glutathione itself 
becomes oxidized but can be reduced to its basal state by glutathione reductase using NADPH as an 
electron donor and be recycled. In any cell, therefore, glutathione can be found in both its reduced and 
oxidized forms and abnormalities in the ratio of reduced to oxidized glutathione can indicate oxidative 
stress. Catalase is another major antioxidant enzyme that detoxifies hydrogen peroxide [124–126], 
whereas superoxide dismutases (SOD’s) inactivate superoxide anions [127]. Regulation of these 
antioxidant enzymes is a major area of investigation [128,129] since it is critical in determining 
cutaneous responses to UV radiation.  
8. Nucleotide Excision Repair and Xeroderma Pigmentosum 
Besides free radical formation, UV directly affects nucleotide base pairing in DNA [130,131]. 
Pyrimidine bases are particularly vulnerable to chemical alteration by absorption of UV energy. 
Shorter-wavelength UV photons, particularly UV-B and UV-C, cleave internal 5–6 double bonds of 
pyrimidines. When this occurs between adjacent pyrimidines, abnormal covalent bonds may form and 
alter the three-dimensional structure of the double helix. Two major photolesions- cyclobutane 
pyrimidine dimers or (6,4)- photoproducts- predictably form in this way after UV exposure, and both 
are highly mutagenic [132]. It is estimated that one day’s worth of sun exposure results in up to 105 
UV-induced photolesions in every skin cell [133]. UV-induced photolesions impair transcription, 
block DNA replication and base pair abnormally. They cause characteristic transition mutations known 
as ―UV signature mutations‖, for example, TT→CC. The abundance of UV signature mutations in 
cancer-regulatory genes among many primary skin cancer isolates strongly supports UV as a  
cancer-causing agent [134–137].  
Figure 5. UV generates oxidative free radicals. UV photons interact with atomic oxygen to 
promote formation of free radical derivatives such as superoxide, hydrogen peroxide and 
the highly reactive hydroxyl radical. Free radicals avidly attack macromolecules such as 
protein, lipid, RNA and DNA, altering their structure and interfering with their function. 
Detoxifying and protective enzymes such as superoxide dismutase, catalase and glutathione 
peroxidase detoxify and reduce levels of oxidative species in the cell.  
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Figure 6. UV-induced cyclobutane dimers- structure (A) and repair by the Nucleotide 
Excision DNA Repair (NER) pathway (B). The NER pathway is mediated by at least eight 
enzymes that work together to identify bulky DNA lesions that distort the structure of the 
double helix, excise the damaged portion and replace the excised region by DNA synthesis 
directed by the complementary strand. Homozygous deficiency in any one of the NER 
enzymes leads to the clinical condition known as Xeroderma Pigmentosum (XP). Although 
not shown, NER can also be initiated in actively transcribed regions of the genome by 
involvement of the Cockayne syndrome proteins A and B. 
 
Nucleotide excision repair (NER) is an evolutionarily-conserved mechanism for repairing  
UV-induced photoproducts and other bulky DNA lesions [138]. The importance of NER in cancer 
resistance is best illustrated by considering the natural history of patients with Xeroderma 
Pigmentosum (XP), a rare UV hypersensitivity syndrome caused by homozygous defects in any one of 
at least eight required effector proteins of a common pathway that executes NER: XPA, ERCC1, 
ERCC3 (XP-B), XPC, ERCC2 (XP-D), DDB2 (XP-E), ERCC4 (XP-F), ERCC5 (XP-G) and POLH. XP 
patients demonstrate profound UV sensitivity and develop characteristic skin changes including 
pigmentary abnormalities, capillary telangiectasias and atrophy on UV-exposed anatomic sites at very 
early ages. Premalignant lesions and skin cancers develop in high frequency and much sooner than in 
unaffected persons. Basal cell carcinomas, squamous cell carcinomas and melanomas often develop 
before the second decade of life, decades before the general population [139]. Moreover, XP-associated 
skin cancers frequently demonstrate ―UV signature mutations‖, clearly indicating the importance of 
NER in the cancer resistance [140]. The NER pathway represents an orchestrated interaction of 
enzymes that function together to repair lesions that alter the three-dimensional structure of DNA. 
After recognition of damage and recruitment of a multiprotein repair complex to the damaged site, the 
damage strand is nicked several nucleotides away on either side of the damaged bases. The damaged 
region is excised and the resulting gap is filled in by a DNA polymerase using the non-damaged strand 
as a template [141–143] (Figure 6). Though only a handful of core factors are necessary and sufficient 
for the repair of UV-induced DNA lesions, there are numerous accessory factors that regulate this 
genome maintenance pathway. While the importance of NER in UV and skin cancer resistance is most 
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clearly demonstrated by the natural history of patients with XP, attention is being paid to the role of 
NER polymorphisms on UV sensitivity and skin cancer incidence in sporadic populations.  
9. Skin Cancer 
Skin cancers are by far the most common malignancies of humans, with well over a million cases 
diagnosed each year [144]. Roughly 1 in 5 Americans will develop skin cancer in their lifetime [145]. 
They account for nearly 15,000 deaths and more than three billion dollars each year in medical costs in 
the United States alone [146,147]. Like many other cancers contributed to by environmental etiologies 
(in this case UV), skin cancer incidence increases markedly with age presumably reflecting the long 
latency between carcinogen exposure and cancer formation. Skin cancers are commonly grouped  
into two main categories, melanoma and non-melanoma skin cancers (NMSC), based on cell of origin 
and clinical behavior. Risk of skin cancer is heavily influenced by UV exposure and by skin 
pigmentation [148] (Figure 7).  
Figure 7. Influence of pigmentation on skin cancer risk. Fair-skinned individuals with low 
levels of melanin in the epidermis display a UV sensitive phenotype, tending to burn rather 
than tan, after UV exposure. Recent data suggest that mutations that contribute to fair 
complexion and tanning impairment, specifically signaling defects in the melanocortin  
1 receptor (MC1R), may also be associated with less efficient DNA repair in melanocytes. 
MC1R-defective individuals not only suffer higher realized doses of UV radiation because 
their skin is less able to block UV photons, but they may also accumulate more mutations 
from UV exposure because of defective DNA repair. 
 
Malignant melanoma of the skin is the deadliest form of skin cancer. Thought to arise from 
epidermal melanocytes, melanoma is a treatment-refractory and metastasis-prone malignancy whose 
incidence has increased steadily and significantly over the last several decades [149]. Whereas only 
one in 1500 Americans was ever diagnosed with melanoma in the 1930s, now roughly one in sixty will 
be affected by the disease [150]. Melanoma accounts for about three quarters of all deaths from skin 
cancers, numbering nearly ten thousand per year in the U.S., despite accounting for far fewer than ten 
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percent of all skin malignancies. Melanoma burden is predictably largest in places with large numbers 
of fair-skinned individuals living in warm, sunny climates [151]. Most melanomas arise out of  
pre-existing moles, therefore having many nevi is another important risk factor for the disease. If 
caught early, many melanomas can be managed by surgical excision alone. However, melanomas are 
quick to invade and metastasize and long-term survival is poor for advanced disease. Even with recent 
progress made in targeted therapy [152–156] and immunotherapy [157,158], melanoma is notoriously 
difficult to treat once it has spread beyond its original site. It is not clear why melanoma incidence has 
increased so dramatically over the past several decades, but it is likely multifactorial, with contributions 
from increased UV exposure, environmental and inherited cancer risk factors and better surveillance 
and earlier detection [151,159–172]. 
Non-melanomatous skin cancers greatly outnumber melanomas in incidence, but fortunately most 
are much easier to treat and have much better long-term prognosis. The two major forms, basal cell 
carcinomas and squamous cell carcinomas, are both derived from epidermal keratinocytes. They are 
less deadly than melanoma mainly due to their tendency to remain confined to their primary site of 
disease, which makes their management much more straightforward. The overwhelming majority of 
keratinocyte malignancies develop in the areas of skin most exposed to UV, such as on the face and 
arms. Most are effectively treated by local control measures alone such as resection, MOHS microsurgery 
or cryosurgery.  
There are strong epidemiologic and molecular data linking all forms of skin cancer to UV  
exposure [173], and it is estimated that UV is causative for nearly 65% of melanoma and 90% of  
non-melanoma skin cancers [174,175]. UV-signature mutations in key cancer-relevant genes such as 
the p53 tumor suppressor in squamous cell carcinoma for example are well-characterized, and exome 
analysis of a panel of melanomas revealed strong genetic evidence for a direct mutagenic role of UV 
radiation in the pathogenesis of melanoma [137,176–183]. Since UV-induced DNA mutations 
represent a major causative factor for melanoma and other skin cancers, it follows that resistance to 
UV-mediated mutagenesis is a critical determinant of skin cancer risk [184].  
10. The Melanocortin 1 Receptor (MC1R) 
The melanocortin 1 receptor (MC1R) is a critical genetic locus involved in pigmentation, the 
adaptive tanning response and skin cancer susceptibility [185–192]. The MC1R is found on the surface 
of melanocytes where it binds to α-melanocyte stimulating hormone (MSH) and transmits differentiation 
signals into the cell through activation of adenylyl cyclase and generation of cAMP [193–195]. cAMP 
signaling leads to activation of the protein kinase A (PKA) cascade which, in turn, leads to increased 
levels and/or activity of many melanogenic enzymes to enhance production and export of melanin by 
melanocytes [90,196,197] (Figure 4). MC1R signaling also decreases UV-mediated mutagenesis by 
enhancing genome maintenance pathways in melanocytes [125,126,192,198]. Loss-of-signaling MC1R 
polymorphisms are commonly found among fair-skinned, sun-sensitive and skin cancer-prone 
populations (e.g., Northern Europeans). The most prevalent MC1R mutations (D84E, R151C, R160W 
and D294H) are commonly referred to as ―RHC‖ (red hair color) alleles because of their association 
with red hair color, freckling and tendency to burn after UV exposure [199,200]. Loss of signaling 
MC1R alleles such as the RHC variants are associated with up to a four-fold increased lifetime risk of 
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melanoma and other skin cancers [201–203]. Overall, there is much evidence placing MC1R as a 
critical determinant of skin cancer risk, and regulation of eumelanin by POMC derived peptides 
depends on genetic context [204]. 
MC1R signaling protects the skin from UV damage by at least two major mechanisms. First, by 
inducing pigment synthesis in melanocytes, MC1R enhance production and accumulation of 
eumelanin in the epidermis. Epidermal melanization blocks penetration of UV into the skin, reducing 
realized doses of UV and decreasing mutagenesis and cancer risk. MC1R signaling also directly 
influences UV resistance of melanocytes by enhancing nucleotide excision DNA repair and  
oxidative resistance. Since MC1R signaling is potentially targetable by agents that influence cAMP 
levels [82,84,205], pharmacologic manipulation of cutaneous cAMP may be a useful approach to 
reduce UV sensitivity and cancer risk. Theoretically, raising cAMP levels in the skin can be accomplished 
either by stimulating its production (e.g., adenylyl cyclase activation) or by impeding its degradation 
(e.g., phosphodiesterase inhibition). Both of these approaches have been quite successful in enhancing 
epidermal melanin levels in animal models [84,206] and each would be expected to be effective even 
in individuals harboring loss-of-signaling functional mutations in MC1R. Alternatively, α-MSH or 
agonistic MC1R peptide ligands would offer more specificity (working only on melanocytes) but might be 
less effective in individuals with inherited MC1R signaling defects [192,193,207].  
11. Conclusions 
One of the greatest risk factors for the development of cutaneous melanoma is having a fair skin 
complexion, which is characterized by low levels of a UV-blocking dark pigment called eumelanin in 
the epidermis. Individuals with light skin pigmentation suffer comparatively more skin damage from 
UV because it is relatively easy for UV rays to penetrate the epidermis to damage both keratinocytes 
and melanocytes in the deeper layers of the epidermis. Fair-skinned individuals are exposed to higher 
―realized‖ doses of UV radiation in the skin and UV-induced mutations, which directly contribute to 
melanoma and other forms of skin cancer, accumulate over time. Much UV-induced pathology, 
including skin cancer, can be avoided by minimizing UV exposure (Table 2).  
We and others are increasingly interested in heritable factors that determine melanoma risk to be 
able to intervene in the carcinogenic process. One of the most important alleles that influences skin 
cancer risk is the melanocortin 1 receptor (MC1R), whose function is central to the adaptive 
pigmentation (tanning) response in the skin. Besides mediating the tanning response, MC1R exerts a 
powerful influence on the ability of melanocytes to repair UV-induced DNA damage by the nucleotide 
excision DNA repair pathway. New insights into the ways in which MC1R and other genes function to 
protect the skin against the harmful consequences of UV may allow the rational development of 
pharmacologic strategies to reduce UV sensitivity and cancer risk.  
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Table 2. UV Safety Tips. 
Sun exposure  Minimize time outdoors during ―peak‖ UV h (10 am to 4 pm). Seek shade as much as 
possible. Be aware that sunlight bounces off reflective surfaces and can reach you even 
under an umbrella or tree. 
 Avoid getting a sunburn. More than 5 sunburns doubles risk of skin cancer. 
 Use sunscreens with a sun protection factor (SPF) >15. Make sure to apply repeatedly 
(especially with sweating or swimming) and as directed. Use sunblocks that offer protection 
from both UV-A and UV-B rays, and be sure to cover often-missed spots- lips, ears, around 
eyes, neck, scalp, hands and feet.  
 Wear protective clothing such as rash guards and tightly woven fabrics. 
 Wear a hat. Wide-brimmed hats protect head, face, ears and neck. If a baseball cap is worn, 
make sure to use sunscreen on ears and neck. 
 Wear UV-protective sunglasses 
 Strength of solar UV increases at high altitude and with less cloud cover. Monitor the UV 
Index (http://www.epa.gov/sunwise/uvindex.html) and plan accordingly. 
 Get Vitamin D safely by relying on diet and supplements rather than UV exposure. 
Artificial Tanning  Do not frequent tanning beds. They can be more dangerous than sunlight. Frequent use of 
artificial tanning products clearly increases risk of each of the major kinds of skin cancer, 
including melanoma.  
 Sunless self-tanning products seem safe but typically offer little sun-blocking UV protection 
on their own.  
Awareness  Examine your skin frequently, at least once a month, head to toe. Use a full-length mirror 
and a hand mirror to check your back, or involve a partner. Have a professional skin 
examination annually.  
 Seek professional medical attention for: 
 Sores that do not heal 
 Changes in moles (growth, irregularity, asymmetry, color changes, elevation, pain, itching) 
 Skin cancers are much more easily treated when caught early. 
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